Compare Medpace Holdings Inc (MEDP) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs M&T Bank Corporation — how do they compare? Medpace Holdings Inc trades at $602 (market cap $16.82B), while M&T Bank Corporation trades at $222.43 (market cap $31.42B). The key difference: M&T Bank Corporation is the larger of the two by market cap, and M&T Bank Corporation pays a 2.76% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and M&T Bank Corporation for 100 Days on average.
| MEDP | MTB | |
|---|---|---|
Market Cap | $16.82B | $31.42B |
Volume | 223,093 | 1,438,219 |
Sector | Health | Financials |
52-Week High | $630.19 | $254.09 |
52-Week Low | $393.42 | $178.63 |
Typical Hold Time | 14 Days | 100 Days |
Enterprise Value | $16.44B | $47.77B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
M&T Bank Corporation (MTB) trades at $216.6, down 0.98% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The bank maintains strong profitability with a 30.85% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights loan growth, AI investments, and a new branch opening, while the company declared a $1.50 dividend payable in September 2026.
The outlook is mixed: analyst consensus is a 'Buy' with a $258.92 price target implying 19.5% upside, but technical weakness and a high proportion of 'Hold' ratings suggest caution. Key risks include volatile cash flows, with a net outflow of $2.01B in 2025, and sensitivity to interest rate changes. Earnings momentum from loan growth and technology investments supports potential recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
